996. Joint Biological Agent Identification and Diagnostic System Influenza A & B and Influenza A Subtyping Detection Kits
Session: Poster Abstract Session: Diagnostic Microbiology: Quality Improvement and Rapid Diagnostics
Friday, October 9, 2015
Room: Poster Hall
Posters
  • 996_IDSA-15-139_PosterPresentation.pptx.pdf (505.7 kB)
  • Background: The Joint Biological Agent Identification and Diagnostic System (JBAIDS, BioFire Defense, Salt Lake City, UT) is the platform for rapid identification of biological warfare and infectious disease agents within the Department of Defense (DoD). Previously, the Centers for Disease Control and Prevention (CDC) Human Influenza Virus Real-Time polymerase chain reaction (RT-PCR) diagnostic panel was successfully ported to the JBAIDS Influenza A & B and Influenza A Subtyping kits. Recently, two novel influenza A strains with pandemic potential, H3N2v and H7N9, have emerged in the US and China, respectively. The Naval Health Research Center, in cooperation with the Joint-Program Management Office Medical Countermeasure Systems (MCS), evaluated the performance of the ported Influenza A & B and Influenza A Subtyping assays on the JBAIDS system.

    Methods: Influenza A & B and Influenza A Subtyping assays ported to the JBAIDS instrument were performed using the Platinum Path Sample Purification Kit (BioFire Diagnostics, Inc.). Reagents were freeze-dried into a single tube containing all necessary constituents (primers, probe, enzyme, and buffers) for real-time PCR that can be stored at ambient temperature. A total of four diagnostic PCR assays were used against cultured strains of influenza A (H3N2, H3N2v, and H7N9) to verify that the JBAIDS Influenza A & B Typing Kit and Influenza A Subtyping Kit can detect the viruses accurately. Subsequently, the assays were evaluated for cross-reactivity with other influenza strains, as well as accuracy, precision, and limit of detection (LOD) for the two emergent strains using both cultured material and clinical samples.

    Results: The study demonstrated that the JBAIDS Influenza A & B and Influenza A Subtyping kits are comparable to the CDC method of detection for the H3N2v and H7N9 strains. The influenza assay kits showed no cross-reactivity against adenovirus, influenza B, or negative clinical samples when tested.

    Conclusion: We confirmed the JBAIDS Influenza kits’ ability to detect both the H3N2v and H7N9 viruses with accuracy and precision. The capability of comprehensive detection of virus strains of concern will allow the DoD to remain prepared in the face of a new influenza emergence and respond with appropriate treatments and effective preventive measures.

    Hayden Thammavong, CTR, Operational Infectious Diseases, Naval Health Research Center, San Diego, CA, Christopher Myers, PhD, Department of Biosurveillance, Naval Health Research Center, San Diego, CA and Gary Brice, CDR/Ph.D, Naval Health Research Center, San Diego, CA

    Disclosures:

    H. Thammavong, None

    C. Myers, None

    G. Brice, None

    << Previous Abstract | Next Abstract

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.